<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448953</url>
  </required_header>
  <id_info>
    <org_study_id>NKTRDP-2015BAI12B08-03</org_study_id>
    <nct_id>NCT02448953</nct_id>
  </id_info>
  <brief_title>Two-field Versus Three-field Lymphadenectomy in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement</brief_title>
  <official_title>Comparison of Lymph Node Dissection Results and Prognosis in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement: Two-field Versus Three-field Lymph Node Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the lymph node dissection results and prognosis in
      thoracic esophageal carcinoma patients without cervical lymph node involvement by
      preoperative CT and/or ultrasound treated by two-field lymphadenectomy or three-field
      lymphadenectomy.Another purpose of this study is to clarify whether the lymph node along the
      right recurrent laryngeal nerve can be taken as the sentinel lymph node which is able to
      indicate neck lymph node metastasis and necessity for three-field lymphadenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal carcinoma is a prevalent and aggressive malignant disease with poor prognosis in
      China. Complete surgical resection with systemic lymph node dissection remains the most
      effective treatment method for this malignancy. Although tree-field lymph node dissection was
      reported to be effective in improving long-term survival in Japan,there is no enough
      evidences yet to demonstrate that three field lymph node dissection is superior to two field
      lymph node dissection in reducing postoperative recurrence and improving long-term survival.
      In this study, the dissection of lymph node adjacent to the right recurrent laryngeal nerve
      would be performed and examined routinely by intraoperative frozen-section. If the lymph node
      is positive, three field lymph node dissection(Cervical-thoracic-upper abdominal
      lymphadenectomy) will be performed, if negative, the patients will be randomly assigned
      either to three-field lymphadenectomy group or two-field lymphadenectomy group. The purpose
      of this large scale multi-center trial is to compare the lymph node dissection results and
      prognosis in thoracic esophageal carcinoma without cervical lymph node involvement treated by
      three-field lymphadenectomy or two-field lymphadenectomy and clarify whether the lymph node
      along the right recurrent laryngeal nerve could be taken as sentinel lymph node indicating
      neck lymph node metastasis and necessity of three-field lymphadenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">786</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>negative lymph node</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>positive lymph node</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two-field lymphadenectomy</intervention_name>
    <description>Thoracic-upper abdominal two-field lymphadenectomy</description>
    <arm_group_label>negative lymph node</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Three-field lymphadenectomy</intervention_name>
    <description>Cervical-thoracic-upper abdominal three-field completely lymphadenectomy</description>
    <arm_group_label>negative lymph node</arm_group_label>
    <arm_group_label>positive lymph node</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed squamous cell esophageal cancer, without any
             previous anti-tumor therapy;

          2. Preoperative clinical TNM stage：cT1b-3N0-1M0;

          3. Adequate cardiopulmonary, liver, brain and kidney functions for esophagectomy either
             via right thoracotomy or VATS;

          4. No evidence of suspicious neck lymph node metastasis (LN short diameter &lt; 0.8cm or LN
             short/long diameter &lt;0.65 by cervical CT and/or ultrasound);

          5. Willing to participate the clinical trial and sign the informed consent before being
             enrolled into clinical trail

        Exclusion Criteria:

          1. Previous use of anti-cancer therapy;

          2. Preoperative clinical TNM stage: N2-3 or M1;

          3. Inadequate cardiopulmonary,liver, brain and kidney function for surgery;

          4. Previous malignancy history.

          5. Suspicious neck lymph node metastasis (LN short diameter ≧0.8cm or LN short/long
             diameter ≧0.65 by cervical CT and/or ultrasound);

          6. Unwilling to participate the clinical trial and refuse to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie He, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yousheng Mao, MD</last_name>
    <phone>8610-87787138</phone>
    <email>maoysherx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhirong Zhang, MD</last_name>
    <phone>8610-87788798</phone>
    <email>zhangzr@cicams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousheng Mao, MD</last_name>
      <phone>8610-87787138</phone>
      <email>maoysherx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhirong Zhang, MD</last_name>
      <phone>8610-87788798</phone>
      <email>zhangzr@cicams.ac.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jie He, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie He</investigator_full_name>
    <investigator_title>president</investigator_title>
  </responsible_party>
  <keyword>Without cervical lymph node involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

